{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"52","value":"17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Percentage of patients alive without disease progression at 2 years. Per RECIST 1.1, Disease Progression is defined as ≥20%increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received pembrolizumab IV over 30 minutes on day 1 of each cycle. Starting on day 7, patients also receive 10 mg of BAY 1895344 PO BID on days 7-9 and 14-16 during cycle 1, and before and after each SBRT treatment during cycle 2 for a total of 9 doses. Beginning cycle 2, patients underwent SBRT starting between days 2 and 8 for 3 fractions with 2-3 days between fractions. Treatment repeated every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity (8 Gy x 3 SBRT). Patients also underwent CT scan and/or PET-CT scan and collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo blood sample collection\n\nComputed Tomography: Undergo CT and/or PET-CT scan\n\nElimusertib: Given PO\n\nPembrolizumab: Given IV\n\nPositron Emission Tomography: Undergo PET-CT scan\n\nQuality-of-Life Assessment: Ancillary studies\n\nStereotactic Body Radiation Therapy: Undergo SBRT","id":"OG000","title":"Treatment (Pembrolizumab, BAY 1895344, SBRT)"}],"paramType":"NUMBER","populationDescription":"Treated patients who were radiologically evaluable.","reportingStatus":"POSTED","timeFrame":"At 2 years","title":"2-year Progression-free Survival","type":"SECONDARY","unitOfMeasure":"percentage of patients"}